October 21, 2014 -- Fab’entech is a biopharmaceutical company that has been specialising in treatments against emerging infectious diseases since 2009.
The rapid emergence of viral diseases such as avian influenza and hemorrhagic fever is creating new pandemic risks. The development of emergency therapies to help infected patients get through the critical stage and help reduce the spread of infection are urgently needed.
To address these public health threats, Fab’entech has developed anti-infective passive immunotherapy solutions, which are based on highly purified specific polyclonal antibodies. Once administered to patients, antibodies neutralize circulating viruses immediately and prevent further spread of infection. This is different to a vaccine.
Fab’entech product’s development and production platform is based on a technology licenced from Sanofi Pasteur and capitalises on existing collaboration and sub-contracting arrangements. The use of this platform allows a rapid response in epidemic situations with a well-established manufacturing process.
Today, Fab’entech has already developed the first treatment against H5N1 influenza, Fabenflu®. In partnership with international health authorities and other partners, Fab’entech is currently evaluating the potential development of a treatment against Ebola.
PRESS CONTACT :
Elise GUEDON, Fab’entech, elise.guedon@fabentech.com
Help employers find you! Check out all the jobs and post your resume.
